OrbiMed Advisors LLC's Form 4 filing
MBX Biosciences, Inc. (MBX) · filed Feb 19, 2025
- Accession no.
- 0000947871-25-000199
- Filed
- Feb 19, 2025, 5:52 PM ET
- Trade date
- Feb 14-18, 2025
- Filing delay
- 5 days
- Rule 10b5-1 plan
- Not checked
This filing lists 4 non-derivative transactions. Open-market purchases total $2.02M. It was filed 5 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| OrbiMed Advisors LLCCIK 0001055951 | Director, 10% Owner |
| OrbiMed Capital GP VII LLCCIK 0001760648 | Director, 10% Owner |
| OrbiMed Genesis GP LLCCIK 0001808744 | Director, 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 14, 2025 | Common Stock | PPurchaseAcquired | +17,962 | $9.90F1 | +$177,823.8 | 3,176,390 | Indirect | Duplicate filing |
| Feb 14, 2025 | Common Stock | PPurchaseAcquired | +29,540 | $9.85F2 | +$290,969 | 3,205,930 | Indirect | Duplicate filing |
| Feb 18, 2025 | Common Stock | PPurchaseAcquired | +49,070 | $10.84F3 | +$531,918.8 | 3,255,000 | Indirect | Duplicate filing |
| Feb 18, 2025 | Common Stock | PPurchaseAcquired | +94,100 | $10.84F3 | +$1,020,044 | 747,887 | Indirect | Duplicate filing |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Represents the weighted average purchase price of the shares of the Issuer's common stock purchased, ranging from a low of $9.58 to a high of $10.20 per share. The Reporting Persons undertake, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares purchased at each separate price.
Referenced by the price of 1 transaction in Table I.
- F2
Represents the weighted average purchase price of the shares of the Issuer's common stock purchased, ranging from a low of $9.80 to a high of $10.00 per share. The Reporting Persons undertake, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares purchased at each separate price.
Referenced by the price of 1 transaction in Table I.
- F3
Represents the weighted average purchase price of the shares of the Issuer's common stock purchased, ranging from a low of $10.25 to a high of $11.46 per share. The Reporting Persons undertake, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares purchased at each separate price.
Referenced by the price of 2 transactions in Table I.